Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Auxin-Inducible Depletion of the Essentialome Suggests Inhibition of TORC1 by Auxins and Inhibition of Vrg4 by SDZ 90-215, a Natural Antifungal Cyclopeptide.

Snyder NA, Kim A, Kester L, Gale AN, Studer C, Hoepfner D, Roggo S, Helliwell SB, Cunningham KW.

G3 (Bethesda). 2019 Mar 7;9(3):829-840. doi: 10.1534/g3.118.200748.

2.

Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency.

Fu J, Becker C, Cao L, Capparelli M, Denay R, Fujimoto R, Gai Y, Gao Z, Guenat C, Karur S, Kim H, Li W, Li X, Li W, Lochmann T, Lu A, Lu P, Luneau A, Meier N, Mergo W, Ng S, Parker D, Peng Y, Riss B, Rivkin A, Roggo S, Schroeder H, Schuerch F, Simmons RL, Sun F, Sweeney ZK, Tjandra M, Wang M, Wang R, Weiss AH, Wenger N, Wu Q, Xiong X, Xu S, Xu W, Yifru A, Zhao J, Zhou J, Zürcher C, Gallou F.

Bioorg Med Chem. 2018 Feb 15;26(4):957-969. doi: 10.1016/j.bmc.2017.09.008. Epub 2017 Sep 7.

PMID:
28919180
3.

Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action.

Bürstner N, Roggo S, Ostermann N, Blank J, Delmas C, Freuler F, Gerhartz B, Hinniger A, Hoepfner D, Liechty B, Mihalic M, Murphy J, Pistorius D, Rottmann M, Thomas JR, Schirle M, Schmitt EK.

Chembiochem. 2015 Nov;16(17):2433-6. doi: 10.1002/cbic.201500472. Epub 2015 Oct 16.

PMID:
26472355
4.

FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p.

Helliwell SB, Karkare S, Bergdoll M, Rahier A, Leighton-Davis JR, Fioretto C, Aust T, Filipuzzi I, Frederiksen M, Gounarides J, Hoepfner D, Hofmann A, Imbert PE, Jeker R, Knochenmuss R, Krastel P, Margerit A, Memmert K, Miault CV, Movva NR, Muller A, Naegeli HU, Oberer L, Prindle V, Riedl R, Schuierer S, Sexton JA, Tao J, Wagner T, Yin H, Zhang J, Roggo S, Reinker S, Parker CN.

Nat Commun. 2015 Oct 12;6:8613. doi: 10.1038/ncomms9613.

5.

Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties.

Krastel P, Roggo S, Schirle M, Ross NT, Perruccio F, Aspesi P Jr, Aust T, Buntin K, Estoppey D, Liechty B, Mapa F, Memmert K, Miller H, Pan X, Riedl R, Thibaut C, Thomas J, Wagner T, Weber E, Xie X, Schmitt EK, Hoepfner D.

Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10149-54. doi: 10.1002/anie.201505069. Epub 2015 Jul 15.

PMID:
26179970
6.

Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.

Fu J, Tjandra M, Becker C, Bednarczyk D, Capparelli M, Elling R, Hanna I, Fujimoto R, Furegati M, Karur S, Kasprzyk T, Knapp M, Leung K, Li X, Lu P, Mergo W, Miault C, Ng S, Parker D, Peng Y, Roggo S, Rivkin A, Simmons RL, Wang M, Wiedmann B, Weiss AH, Xiao L, Xie L, Xu W, Yifru A, Yang S, Zhou B, Sweeney ZK.

J Med Chem. 2014 Oct 23;57(20):8503-16. doi: 10.1021/jm500862r. Epub 2014 Oct 13.

PMID:
25310383
7.

Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L, Helliwell SB, Hoepfner D, Knapp B, Riedl R, Roggo S, Schuierer S, Studer C, Porco JA Jr, Pelletier J, Movva NR.

ACS Chem Biol. 2013 Jul 19;8(7):1519-27. doi: 10.1021/cb400158t. Epub 2013 May 7.

8.

Oxysterols direct immune cell migration via EBI2.

Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, Guerini D, Baumgarten BU, Roggo S, Wen B, Knochenmuss R, Noël S, Gessier F, Kelly LM, Vanek M, Laurent S, Preuss I, Miault C, Christen I, Karuna R, Li W, Koo DI, Suply T, Schmedt C, Peters EC, Falchetto R, Katopodis A, Spanka C, Roy MO, Detheux M, Chen YA, Schultz PG, Cho CY, Seuwen K, Cyster JG, Sailer AW.

Nature. 2011 Jul 27;475(7357):524-7. doi: 10.1038/nature10280.

9.

The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease.

Schmitt EK, Riwanto M, Sambandamurthy V, Roggo S, Miault C, Zwingelstein C, Krastel P, Noble C, Beer D, Rao SP, Au M, Niyomrattanakit P, Lim V, Zheng J, Jeffery D, Pethe K, Camacho LR.

Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5889-91. doi: 10.1002/anie.201101740. Epub 2011 May 11. No abstract available.

PMID:
21563281
10.

Natural product-likeness score and its application for prioritization of compound libraries.

Ertl P, Roggo S, Schuffenhauer A.

J Chem Inf Model. 2008 Jan;48(1):68-74. Epub 2007 Nov 23.

PMID:
18034468
11.

The scaffold tree--visualization of the scaffold universe by hierarchical scaffold classification.

Schuffenhauer A, Ertl P, Roggo S, Wetzel S, Koch MA, Waldmann H.

J Chem Inf Model. 2007 Jan-Feb;47(1):47-58.

PMID:
17238248
12.

Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics.

Hanessian S, Yun H, Hou Y, Yang G, Bayrakdarian M, Therrien E, Moitessier N, Roggo S, Veenstra S, Tintelnot-Blomley M, Rondeau JM, Ostermeier C, Strauss A, Ramage P, Paganetti P, Neumann U, Betschart C.

J Med Chem. 2005 Aug 11;48(16):5175-90.

PMID:
16078837
13.

Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheads.

Ullman BR, Aja T, Chen N, Diaz JL, Gu X, Herrmann J, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs JJ, Linton SD, Meduna SP, Nalley K, Robinson ED, Roggo SP, Sayers RO, Schmitz A, Ternansky RJ, Tomaselli KJ, Wu JC.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3632-6.

PMID:
15964758
14.

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.

Linton SD, Aja T, Allegrini PR, Deckwerth TL, Diaz JL, Hengerer B, Herrmann J, Jahangiri KG, Kallen J, Karanewsky DS, Meduna SP, Nalley K, Robinson ED, Roggo S, Rovelli G, Sauter A, Sayers RO, Schmitz A, Smidt R, Ternansky RJ, Tomaselli KJ, Ullman BR, Wiessner C, Wu JC.

Bioorg Med Chem Lett. 2004 May 17;14(10):2685-91.

PMID:
15109679
15.

Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications.

Ullman BR, Aja T, Deckwerth TL, Diaz JL, Herrmann J, Kalish VJ, Karanewsky DS, Meduna SP, Nalley K, Robinson ED, Roggo SP, Sayers RO, Schmitz A, Ternansky RJ, Tomaselli KJ, Wu JC.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3623-6.

PMID:
14505683
16.

Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.

Linton SD, Karanewsky DS, Ternansky RJ, Chen N, Guo X, Jahangiri KG, Kalish VJ, Meduna SP, Robinson ED, Ullman BR, Wu JC, Pham B, Kodandapani L, Smidt R, Diaz JL, Fritz LC, von Krosigk U, Roggo S, Schmitz A, Tomaselli KJ.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2973-5.

PMID:
12270186
17.

Inhibition of BACE, a promising approach to Alzheimer's disease therapy.

Roggo S.

Curr Top Med Chem. 2002 Apr;2(4):359-70. Review.

PMID:
11966460
18.

Synthesis of tools for target identification of the anti-apoptotic compound CGP 3466; Part I.

Zimmermann K, Roggo S, Kragten E, Fürst P, Waldmeier P.

Bioorg Med Chem Lett. 1998 May 19;8(10):1195-200.

PMID:
9871734
19.

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl.

Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, Furst P.

J Biol Chem. 1998 Mar 6;273(10):5821-8.

Supplemental Content

Support Center